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Non‑invasive pulmonary artery 
pressure estimation by electrical 
impedance tomography 
in a controlled hypoxemia study 
in healthy subjects
Martin Proença1,2*, Fabian Braun1,2, Mathieu Lemay1, Josep Sol 1, Andy Adler3, 
Thomas Riedel4,5, Franz H. Messerli6, Jean‑Philippe Thiran2,7, Stefano F. Rimoldi6 & 
Emrush Rexhaj6
Pulmonary hypertension is a hemodynamic disorder defined by an abnormal elevation of pulmonary 
artery pressure (PAP). Current options for measuring PAP are limited in clinical practice. The aim 
of this study was to evaluate if electrical impedance tomography (EIT), a radiation‑free and non‑
invasive monitoring technique, can be used for the continuous, unsupervised and safe monitoring 
of PAP. In 30 healthy volunteers we induced gradual increases in systolic PAP (SPAP) by exposure to 
normobaric hypoxemia. At various stages of the protocol, the SPAP of the subjects was estimated by 
transthoracic echocardiography. In parallel, in the pulmonary vasculature, pulse wave velocity was 
estimated by EIT and calibrated to pressure units. Within‑cohort agreement between both methods 
on SPAP estimation was assessed through Bland–Altman analysis and at subject level, with Pearson’s 
correlation coefficient. There was good agreement between the two methods (inter‑method difference 
not significant (P > 0.05), bias ± standard deviation of − 0.1 ± 4.5 mmHg) independently of the degree of 
PAP, from baseline oxygen saturation levels to profound hypoxemia. At subject level, the median per‑
subject agreement was 0.7 ± 3.8 mmHg and Pearson’s correlation coefficient 0.87 (P < 0.05). Our results 
demonstrate the feasibility of accurately assessing changes in SPAP by EIT in healthy volunteers. If 
confirmed in a patient population, the non‑invasive and unsupervised day‑to‑day monitoring of SPAP 
could facilitate the clinical management of patients with pulmonary hypertension.
Pulmonary hypertension (PH) is a pathophysiological condition characterized by a persistent and abnormal 
elevation of mean pulmonary artery pressure (PAP) above 25 mmHg, as assessed by right heart  catheterization1. 
Chronic PH, with left heart disease as its most common cause, affects at least 0.3% of the general population and 
more than 60% of patients with moderate or severe heart  failure2,3. The long-term follow-up of patients with PH 
relies in part on spot PAP measurements performed during clinic visits at intervals of several  months1. How-
ever, assessing changes in PAP on a daily basis has shown to improve outcomes in patients with left heart failure 
equipped with an implantable  monitor4, as increases in intracardiac pressures occur days or weeks before the 
onset of  symptoms5. The availability of day-to-day trends in PAP for the clinician allows anticipating worsening 
conditions, thereby significantly reducing hospitalization  rates4. However, while implantable monitors provide 
valuable insights in the patient’s response to therapy and allow earlier adaptation of treatment, they remain a 
highly invasive solution. Transthoracic echocardiography (TTE)—although non-invasive—is incompatible with 
daily unsupervised monitoring because of its dependency on a trained operator to perform the measurement and 
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its inapplicability in 20–50% of patients due to unmeasurable tricuspid  regurgitation6,7. A non-invasive solution 
able to provide PAP estimates on a day-to-day basis without supervision does currently not exist.
In this context, we have recently proposed a non-invasive and unsupervised method for the continuous 
monitoring of  PAP8 and demonstrated its feasibility in a model-based  simulation9. Our technique is based on 
electrical impedance tomography (EIT), a non-invasive and radiation-free medical imaging method allowing 
continuous monitoring at the  bedside10. The main strength of EIT resides in its ability to monitor changes in the 
intra-thoracic distribution of electrical impedance with a high temporal resolution. Thus, impedance changes 
induced by respiratory and cardiovascular activity (e.g. changes in air volume in the lungs or in blood volume 
in the heart and arteries) can be monitored in real-time. In particular, changes in the pulsatility of the pulmo-
nary arteries have shown to produce variations in EIT images in the pulmonary region, allowing assessment of 
PAP-related information from  EIT11. We present hereafter the first experimental evidence of our method in a 
preclinical controlled hypoxemia study in 30 healthy participants.
Methods
The study was conducted in accordance with the amended Declaration of Helsinki. The protocol was approved 
by the Ethical Committee of the Canton of Bern (KEK), Switzerland (KEK Application 200/12), and registered 
at ClinicalTrials.gov (NCT02969486). All participants provided written informed consent.
Measurement principle. The velocity at which a pressure wave travels along an artery—the pulse wave 
velocity (PWV)—is linked to the elastic properties of the arterial  wall12. As the arterial wall stiffens, the PWV 
increases and a larger blood pressure pulse is required to expand the wall. Thus, PWV and blood pressure are 
intrinsically linked. The PWV between two locations separated by a distance D along an arterial pathway can be 
calculated as PWV = D/PTT, where PTT is the pulse transit time. For blood pressure-related applications, esti-
mating D—which is considered constant—is unnecessary as a calibration function f(·) is eventually required for 
converting the estimated PWV values to pressure units (mmHg). Therefore, monitoring changes in PAP using 
the PWV directly relies on monitoring changes in PTT: PAP = f(PTT). In our approach, the first arterial location 
is the pulmonary valve, and the second one a distal location in the lungs. As further explained hereafter, we use 
EIT to detect the arrival of the pressure pulse in the lungs. However, detecting in a non-invasive way the time of 
opening of the pulmonary valve is particularly complex. This is why in practice the PTT is often approximated 
by the pulse arrival time, which uses the R-wave peak of the electrocardiogram (ECG) as reference time instead 
of the opening of the  valve13. In the present study, an ECG signal was thus measured along with the EIT data, and 
the pulse arrival time was used as a surrogate measure of the PTT.
Participants and experimental protocol. We enrolled thirty healthy participants in our study. Exclu-
sion criteria were age below eighteen, known heart or pulmonary disease, pacemaker or implantable cardio-
verter defibrillator, pregnancy or lactation.
In order to induce PAP variations, the subjects breathed nitrogen-enriched air through a mask connected 
to an altitude simulator (AltiTrainer, SMTEC, Switzerland). Normobaric hypoxemia causes vasoconstriction 
in the pulmonary arterial tree and therefore induces elevations of PAP. The peripheral capillary oxygen satura-
tion  (SpO2) of the subjects was continuously monitored using the Radical-7 device (Masimo, USA), whereas 
their systolic pulmonary artery pressure (SPAP) was measured periodically by TTE. Each subject was lying in 
supine position and underwent seven 2-min EIT and ECG measurements at various oxygen saturation levels: 
two measurements in normoxemia (~ 540 m,  SpO2 ≥ 95%), two measurements in mild hypoxemia (~ 4200 m, 
90% > SpO2 ≥ 80%), two measurements in profound hypoxemia (~ 5400 m, 80% > SpO2 ≥ 65%), and at the end 
again one baseline measurement in normoxemia. Immediately after each EIT measurement, the subjects were 
asked to turn on their left side to measure their SPAP by TTE.
The echocardiographic measurements were performed with a real-time, phased-array sector scanner (Acuson 
Sequoia 512, Siemens, Germany) with an integrated color Doppler system and transducers containing crystal 
sets for 2-dimensional imaging (5.0 MHz with second harmonic technology) and for continuous-wave Doppler 
recording (2.5 MHz). After localization of tricuspid regurgitation via Doppler color flow imaging, the maximal 
tricuspid regurgitation velocity  vmax was measured by means of continuous-wave Doppler ultrasound. The right 
atrioventricular pressure gradient ΔP was estimated using the modified Bernoulli equation (ΔP = 4 vmax2), as 
previously validated by our group in hypoxemia against invasive  measurements14. The SPAP was estimated 
as ΔP + RAP, where RAP (right atrial pressure) was assumed to be 3 mmHg15. To reduce the impact of TTE’s 
 imprecision16, each reported SPAP value is the average of at least three consecutive measurements. The maxi-
mal deviation among averaged values was verified to be systematically ≤ 4 mmHg. The EIT data were acquired 
using the 16-electrode Goe-MF II device (CareFusion, Germany) in combination with 16 gel electrodes (Ambu 
BR-50-K, Ambu, Denmark) placed around the participants’ thorax in a transversal plane at the level of the fifth 
intercostal space. An ECG was synchronously recorded using the ECG100C module (Biopac Systems, Inc., USA) 
and fed into the auxiliary input of the EIT device. The EIT data were acquired using an injection frequency of 
100 kHz and a frame rate of 25 per second. The ECG signal was sampled at 325 Hz. The EIT data were recon-
structed into images of 64 × 64 pixels with Matlab (MathWorks, Natick, USA) using the EIDORS  toolbox17. The 
reconstruction was performed using the 2.5D human thorax model of EIDORS and the GREIT algorithm with 
the recommended  settings18.
Estimation of the pulmonary PTT. The estimation of the pulmonary PTT for each 2-min EIT recording 
was fully automated and is illustrated in Fig. 1. As a first step, the EIT time signal at each pixel was high-pass 
filtered (0.65 Hz) using zero-phase filtering. Each 2-min EIT signal at each pixel was then averaged to one rep-
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resentative pulse through ECG-gated ensemble  averaging19. Then, a pulmonary region of interest (ROI), defined 
as those pixels depicting a lung-like behavior and a significant pulsatility, was automatically segmented from the 
EIT images. To do so, a similar approach to the one proposed previously was  implemented9,20. The pulmonary 
ROI was defined as those pixels showing coherent phase with the average cardiac-related EIT signal (average 
signal over all pixels). The ROI was then limited to pixels showing a pulsatile amplitude exceeding a threshold 
equal to the first quartile of the distribution of amplitude values. The pulmonary PTT was estimated at each pixel 
in the ROI from the ensemble average pulse using the maximum of its first time derivative. Possible outliers were 
automatically rejected using the median absolute deviation  method21. The final pulmonary PTT was obtained by 
averaging all non-rejected PTT estimates.
EIT‑based SPAP estimation. In order to translate our PTT estimates into actual SPAP values, we made 
use of a calibration function f(·) linking both quantities as SPAP = f(PTT). Although the function f(·) is typically 
an inverse  exponential22,23, monitoring relatively small PAP changes around a certain baseline value allows to 
locally approximate f(·) by a simple affine function: SPAP = α·PTT + β24. In this study we considered the practical 
use case where only the β coefficient is adjusted for each subject, while the α coefficient remains the same for 
all subjects. The value of the α coefficient was obtained through linear regression of the PTT values onto their 
corresponding SPAP values at a cohort level, leading to an α value of − 710 mmHg/s. Being a simple offset, the 
Figure 1.  Estimation of the pulmonary PTT (as the pulse arrival time) from ECG and EIT data. After (i) 
EIT image reconstruction, each pixel-wise EIT time signal is (ii) high-pass filtered and summarized to one 
representative pulse through ECG-gated ensemble averaging, resulting in (iii) N cardio-synchronous ensemble 
average pulses for the N pixels of the EIT image sequence. (iv) The modulus and phase of all N ensemble 
average pulses is calculated and a pulmonary region of interest of M pixels is obtained by finding all pixels with 
significant pulsatile amplitude showing coherent phase with the average cardiac-related EIT signal. (v) For each 
of the M pulmonary pixels, the PTT is estimated using the maximum of its first time derivative. Finally, the 
global pulmonary PTT is obtained by averaging the PTT values of all M pulmonary pixels after outlier rejection 
using the MAD method. ECG electrocardiography, EIT electrical impedance tomography, PTT pulse transit 
time, MAD median absolute deviation.
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β coefficient does not require inducing PAP variations to be calibrated and was therefore adjusted for each sub-
ject using the baseline measurements in normoxemia only, as β = average (SPAP − α·PTT). We also investigated 
the calibration scenario where the α coefficient is adjusted at a subject level; although impractical as it requires 
inducing PAP variations in the patient, this analysis allows quantifying the best achievable agreement using our 
proposed approach.
Statistical analysis. The agreement between the estimated EIT-derived SPAP values  (SPAPEIT) and the 
TTE-derived SPAP values  (SPAPTTE) at a cohort-wise level was evaluated via Bland–Altman  analysis25. Using 
 SPAPTTE as reference, the accuracy of  SPAPEIT was evaluated using the statistical bias (average value of the dif-
ferences between both methods), and its precision was evaluated using the standard deviation (SD) of the dif-
ferences. These accuracy and precision assessments were also performed after grouping all measurements into 
three groups (normoxemia, mild hypoxemia, and profound hypoxemia). Paired-sample t-tests were used to 
determine if the difference between both methods was significant (at the 5% significance level). The agree-
ment of  SPAPEIT with  SPAPTTE was also evaluated at a subject-wise level. Finally, the ability of EIT in tracking 
SPAP changes in the individual participant was evaluated using Pearson’s correlation coefficient (5% significance 
level). The distribution of the subject-wise performance values was reported using the median, the first (Q1) and 
third (Q3) quartiles, and the range (minimal and maximal values).
Results
Three volunteers had no measurable tricuspid regurgitation—needed for the estimation of  SPAPTTE—and in 
three subjects the EIT signals were non-interpretable for technical reasons, leaving us with a total of 24 subjects. 
In two participants, the recording of the ECG signal during the first measurement in normoxemia failed, leaving 
us with 6 measurements instead of 7 for these two subjects. Thus, a total of 166 paired TTE-EIT data points were 
obtained (70 in normoxemia, 48 in mild hypoxemia, and 48 in profound hypoxemia).  SPAPTTE was significantly 
increased (P < 0.001) during mild (25.1 ± 4.3 mmHg) and profound hypoxemia (32.0 ± 5.2 mmHg) as compared 
to baseline normoxemic values (19.5 ± 2.9 mmHg). The characteristics of the study participants are presented 
in Table 1. None of the participants suffered from PH, nor any complication during the tests. Systemic blood 
pressure and cardiac function were within the normal range in all participants.
Figure 2 (upper left) depicts the Bland–Altman plot for the entire cohort. Each  SpO2 level (normoxemia, mild 
hypoxemia, and profound hypoxemia) is represented by a different symbol. The solid line shows the cohort-wise 
accuracy (bias) of − 0.1 mmHg, and the two dashed lines encompass the 95% limits of agreement (bias ± 1.96 SD), 
thus depicting a cohort-wise precision (SD) of 4.5 mmHg. Bland–Altman plots for each  SpO2 level are shown in 
the lower panel of Fig. 2. Finally, the upper right panel depicts the correlation plot between  SPAPEIT and  SPAPTTE, 
with a cohort-wise Pearson’s correlation coefficient of 0.76 (P ≪ 0.001).
Table 2 reports the cohort-wise agreement between  SPAPEIT and  SPAPTTE at various levels of oxygen satura-
tion. In all cases, the null hypothesis that the paired differences between both methods come from a normal 
distribution with mean equal to zero could not be rejected at the 5% significance level.
Table 1.  Biometric characteristics of the 24 participants. The data are given as “mean (standard deviation, 
SD)”, or as “count (percentage)” when indicated. For peripheral oxygen saturation  (SpO2) and systolic 
pulmonary artery pressure, the data are provided as a function of the saturation level: normoxemia 
 (SpO2 ≥ 95%), mild hypoxemia (90% > SpO2 ≥ 80%), and profound hypoxemia (80% > SpO2 ≥ 65%). TTE 
transthoracic echocardiography.
Subject characteristics (n = 24) Mean (SD), or count (percentage)
Age (year) 33.6 (9.1)
Height (cm) 175.4 (5.7)
Weight (kg) 74.3 (11.5)
Body mass index (kg/m2) 24.1 (3.1)
Gender, male 20 (83%)
Active smoking 1 (4%)
Systemic arterial pressure (mmHg)
Systolic 126.2 (14.2)
Diastolic 74.8 (8.8)
Heart rate (bpm) 60.2 (9.8)
Peripheral oxygen saturation,  SpO2 (%)
Normoxemia 96.4 (1.2)
Mild hypoxemia 85.4 (4.0)
Profound hypoxemia 74.3 (5.4)
TTE-derived systolic pulmonary artery pressure (mmHg)
Normoxemia 19.5 (2.9)
Mild hypoxemia 25.1 (4.3)
Profound hypoxemia 32.0 (5.2)
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Table 3 shows the agreement and correlation between  SPAPEIT and  SPAPTTE for all participants at the subject 
level. The distributions of all values are depicted using the three quartiles (Q1, median, and Q3), and the range 
(minimal and maximal values). Thus, a median per-subject difference of 0.7 ± 3.8 mmHg (bias ± SD) was found 
between both methods, and a median Pearson’s correlation coefficient of 0.87. The correlation was found to be 
significant at the 5% significance level for all participants but four, three of which with P < 0.10 and one, with the 
lowest per-subject correlation of 0.63, with P = 0.12.
In order to evaluate the best achievable agreement between  SPAPEIT and  SPAPTTE, the calibration scenario 
where the α coefficient is adjusted at a subject level was also investigated. The cohort-wise accuracy (bias) and 
precision (SD) decreased to 0.0 and 2.8 mmHg, respectively, and the cohort-wise Pearson’s correlation coefficient 
increased to 0.90 (P ≪ 0.001). At a subject level, a median per-subject difference of 0.0 ± 2.6 mmHg (bias ± SD) 
Figure 2.  Upper left: Bland–Altman plot depicting the cohort-wise agreement between the EIT-derived 
SPAP  (SPAPEIT) and the TTE-derived SPAP  (SPAPTTE). Each type of symbol represents an oxygen saturation 
level  (SpO2), showing n = 70 paired values in normoxemia (filled circle,  SpO2 ≥ 95%), n = 48 paired values in 
mild hypoxemia (filled square, 90% > SpO2 ≥ 80%), and n = 48 paired values in profound hypoxemia (filled 
triangle, 80% > SpO2 ≥ 65%), for a total of n = 166 paired values. In terms of accuracy, an average difference 
(bias) of − 0.1 mmHg was found between both methods and is depicted as a solid line. In terms of precision, 
the standard deviation (SD) of the paired differences was found to be 4.5 mmHg, resulting in 95% limits 
of agreement (bias ± 1.96 SD) of [− 8.9, 8.7] mmHg, depicted as dashed lines. Upper right: Correlation plot 
between  SPAPEIT and  SPAPTTE, with a cohort-wise Pearson’s correlation coefficient of 0.76 (P ≪ 0.001). Bottom: 
Bland–Altman plots for each  SpO2 level separately. EIT electrical impedance tomography, TTE transthoracic 
echocardiography, SPAP systolic pulmonary artery pressure.
Table 2.  Agreement between the EIT-derived and TTE-derived SPAP estimates at the cohort-wise level. 
The distributions over the entire cohort (n = 166 paired measurements) are shown as “mean ± standard 
deviation”. The agreement is also depicted as a function of the oxygen saturation level  (SpO2), comparing the 
distributions in normoxemia  (SpO2 ≥ 95%), mild hypoxemia (90% > SpO2 ≥ 80%), and profound hypoxemia 
(80% > SpO2 ≥ 65%). In all cases, the distribution of the differences (EIT − TTE) between both methods 
showed to be non-significantly different from a zero-mean normal distribution at the 5% significance level. 
EIT electrical impedance tomography, TTE transthoracic echocardiography, SPAP systolic pulmonary artery 
pressure. † Paired-sample t-test: Not significant at the 5% significance level (P > 0.05).
Cohort-wise measurements TTE (mmHg) EIT (mmHg) EIT − TTE (mmHg)
All measurements combined (n = 166) 24.7 ± 6.6 24.6 ± 6.4  − 0.1 ± 4.5†
Normoxemia (n = 70) 19.5 ± 2.9 19.5 ± 3.7 0.0 ± 2.6†
Mild hypoxemia (n = 48) 25.1 ± 4.3 26.3 ± 5.4 1.2 ± 4.5†
Profound hypoxemia (n = 48) 32.0 ± 5.2 30.4 ± 4.7  − 1.6 ± 6.0†
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was found between  SPAPEIT and  SPAPTTE. The subject-wise Pearson’s correlation coefficients being unaffected 
by the value of the α coefficient, remained unchanged.
Discussion
There is currently no non-invasive and unsupervised solution for the day-to-day monitoring of pulmonary 
artery pressure in patients with chronic pulmonary hypertension. This study presents experimental evidence 
of the feasibility to monitor SPAP non-invasively using EIT in 24 healthy subjects through the measurement 
of the pulmonary PTT. Changes in SPAP were induced by hypoxemic vasoconstriction and compared to SPAP 
values obtained from echocardiographic measurements. Results demonstrate no significant difference between 
both methods, irrespective of the level of SPAP, from normoxemia to profound hypoxemia. This agreement was 
also verified at a subject level, along with strong and significant subject-wise Pearson’s correlation coefficients, 
thereby confirming the ability of our proposed approach in tracking intra-subject changes in PAP via EIT. When 
adjusting the α calibration coefficient at a subject level, a general ~ 35% precision improvement was observed; 
however, given the impractical applicability of such a calibration procedure, these results only serve to illustrate 
the best achievable agreement obtainable with our method.
While our results demonstrate excellent accuracy (bias of − 0.1 mmHg), their moderate precision (standard 
deviation of 4.5 mmHg) may lead to occasional large differences in individual measurements. A part of this 
imprecision may be attributed to our use of TTE as  reference16, highlighting the need for further comparison 
studies against an invasive reference. However, because EIT measures continuously and without supervision, 
its precision can easily be improved by repeating and averaging measurements, as averaging N measurements 
decreases the standard deviation of the error by a factor 
√
N 26. For instance, averaging 3 measurements already 
brings the standard deviation down from 4.5 to 2.6 mmHg. Considering 2-min measurements as is the case in 
our study, this suggests that wearing an EIT system for only a few minutes is sufficient to obtain averages with 
higher precision.
Cardiovascular applications of EIT have received increasing attention over the last decade, from investiga-
tions on cardiac output to pulmonary  perfusion27–30. The use of EIT for monitoring patients with PH has been 
proposed previously by Smit et al.11. However, although they, with high accuracy, could discriminate between 
patients and healthy subjects, no correlation was found between EIT-based features and the severity of the dis-
ease. Furthermore, as all their patients suffered from advanced disease, they could not extrapolate their results to 
early stages. In contrast, our PWV-based approach for PAP monitoring is thought to be particularly well-suited 
for detecting early changes in pulmonary hemodynamics. This is due to the direct link between PWV and arte-
rial  distensibility12, which is an even stronger predictor of survival than PAP  itself31,32. In addition, the inverse 
exponential nature of the PTT-PAP relationship suggests higher measurement sensitivity at lower pressures, 
from mild to moderate PH. Conversely, our approach may suffer from lower sensitivity at severe hypertensive 
stages. From a model-based  study9, this decrease in the sensitivity of our approach may begin at mean PAP values 
of ~ 40–50 mmHg (SPAP ~ 60–75 mmHg), which we did not investigate in the present study. This is concordant 
with findings from an intravascular ultrasound  study23, where arterial distensibility compared to PAP progres-
sively reached a plateau starting from a mean PAP of ~ 40 mmHg, as the arteries were approaching their elastic 
limit. A direct consequence of the non-linear nature of the PTT-PAP relationship is an expectable decrease in 
the magnitude of the α calibration coefficient as PAP increases, suggesting that applying our proposed approach 
to a large patient population might require prior training of the α calibration coefficient over a large range of 
PAP values covering the physiological range.
When compared to the only currently available non-invasive PAP measuring solution that is TTE, EIT has 
several advantages, such as its lower cost, and its ability to provide unsupervised monitoring. While TTE requires 
an experienced echocardiographer for accurate measurement of SPAP, no particular training other than attaching 
an electrode belt to a patient is required for EIT. Furthermore, the applicability of EIT exceeds that of TTE, for 
which 20–50% of patients have no measurable tricuspid  regurgitation6,7. Lastly, because EIT provides continu-
ous measurements, our method has the potential of detecting minute variations in pulmonary hemodynamics, 
otherwise missed by intermittent methods such as TTE. This could prove particularly useful in contexts of care 
such as intensive care units, where the use of right heart catheterization has been sharply reduced over the last 
decades after several randomized controlled trials failed to demonstrate any decrease in morbidity and mortality 
following its use in critically ill and hemodynamically unstable  patients33–36. In this context, EIT could be used to 
carry on the monitoring of PAP after earlier removal of the catheter, thereby reducing the risks associated with 
Table 3.  Agreement between the EIT-derived and TTE-derived systolic pulmonary artery pressure estimates 
at the subject-wise level. For each subject, the mean and standard deviation (SD) of the paired differences 
between both methods was computed, along with Pearson’s correlation coefficient. The distributions over all 
participants are shown using the three quartiles (Q1, median, and Q3), and the range (minimal and maximal 
values). EIT electrical impedance tomography, TTE transthoracic echocardiography. *Significant at the 5% 
significance level (P < 0.05).
Subject-wise measurements Minimum Q1 Median Q3 Maximum
Mean of the differences (mmHg)  − 5.4  − 2.6 0.7 1.4 4.8
SD of the differences (mmHg) 1.6 2.9 3.8 4.7 6.1
Pearson’s correlation coefficient 0.63 0.78* 0.87* 0.92* 0.99*
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its maintenance. In patients lacking invasive monitoring, EIT could provide valuable information by measuring 
continuous PAP trends.
A potentially limiting aspect of our approach is that it does not directly estimate absolute values of PAP, but 
absolute changes of PAP around an arbitrary baseline value. Setting this baseline value requires a calibration, 
such as a TTE-derived measurement of the patient’s SPAP during a visit in the clinics. In other contexts such 
as the aforementioned intensive care settings, the EIT device could simply be calibrated using the invasive PAP 
before catheter removal.
Another potential limitation of our approach is the use of the pulse arrival time as a surrogate of the 
PTT, which may make it sensitive to factors affecting the pre-ejection period, such as ventricular contractil-
ity  changes13. Also, EIT belt position changes (e.g. rotations or vertical shifts) may affect the accuracy of our 
approach, mainly at severe hypertensive  levels37. The use of 3D  EIT38, shirt-embedded EIT  belts39, or torso shape 
detection  methods40 are various possible strategies that should help minimize the influence of such belt displace-
ments. The well-known limited signal-to-noise ratio of cardiovascular-related EIT  signals10 is another aspect 
that may occasionally challenge our approach, as observed in the three subjects rejected for this reason prior 
to analysis in our study (10% failure rate). Also, considering one single global PTT value in our approach for 
the entire lung vasculature may lead to inaccuracies in cases of heterogeneous PTT distributions, e.g. in case of 
ventilation/perfusion mismatch. In such cases, an analysis based on subregions of interest should be performed, 
but is out of the scope of the present study, where healthy subjects were investigated. Lastly, the performance of 
our approach needs to be assessed versus the invasive gold standard, and on a patient population, for a formal 
validation. Preliminary results compared to the invasive method proved promising in neonatal  lambs41.
In conclusion, the results of our study suggest that changes in PAP may be reliably monitored by a novel, 
non-invasive, continuous and unsupervised approach based on EIT. If confirmed in a patient population, these 
findings may open new perspectives for the day-to-day follow-up of patients with pulmonary hypertension, 
offering a better control of early disease progression and symptoms. Our method may also be particularly use-
ful in intensive care settings, where the benefit-to-risk ratio associated with an invasive monitoring approach 
often dissuade clinicians.
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